Eli Lilly and Company
2,861
184
332
2,183
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
8.9%
256 terminated/withdrawn out of 2861 trials
89.5%
+3.0% vs industry average
33%
945 trials in Phase 3/4
72%
1581 of 2183 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (2861)
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Role: lead
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
Role: collaborator
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Role: lead
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Role: lead
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Role: lead
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Role: lead
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Role: lead
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Role: lead
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Role: lead
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Role: collaborator
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Role: lead
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Role: lead
Tirzepatide for Treatment of CCCA
Role: collaborator
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Role: lead
New Assessment System in Measuring Symptom Distress in Cancer Patients
Role: collaborator
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Role: collaborator
A Study of LY4515100 in Healthy Participants
Role: lead
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Role: lead
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Role: collaborator
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Role: lead